---
title: "AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Access and distribution"
description: "Formulary evidence on AD109 (aroxybutynin-atomoxetine, Oxnimbi) in Obstructive sleep apnea: Access and distribution. Topics: Commercial readiness activities before a potential launch, Payer discussions to inform potential 2027 formulary inclusion, Planned distribution model: specialty pharmacy partners and a patient services hub, Planned field sales force and prescriber targets, and 4 further topics. 8 evidence topics quoted from 4 sources."
canonical: "https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description/access-and-distribution"
published: "2026-11-18T10:43:47-05:00"
modified: "2026-11-18T10:43:47-05:00"
---

# AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Access and distribution

<a id="heading-2.1.2.11"></a>

## 2.1.2.11 Access and Distribution

<a id="topic-2.1.2.11-1"></a>

### Commercial readiness activities before a potential launch

> “Continued to advance commercial readiness activities, including market access and payer engagement, commercial team and go-to-market build-out, and manufacturing and distribution preparation, to support a potential U.S. launch of Oxnimbi, subject to FDA approval.”

Source: [Apnimed third quarter results release (2026)](https://ir.apnimed.com/news-releases/news-release-details/apnimed-reports-third-quarter-2026-financial-results-and)

<a id="topic-2.1.2.11-2"></a>

### Payer discussions to inform potential 2027 formulary inclusion

> “Market Access & Reimbursement. We are conducting payer information exchanges and engaging in early, non-binding formulary contracting discussions with leading Medicare Part D and Commercial payers to inform potential 2027 formulary inclusion for Oxnimbi, subject to FDA approval. These activities are designed to understand evidence requirements, anticipated utilization management approaches, and potential pathways for future coverage.”
> “Market research conducted by us among payers suggested that payers see a clear unmet need in OSA, as current OSA therapies are not curative and do not address the root cause of OSA.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-2.1.2.11-3"></a>

### Planned distribution model: specialty pharmacy partners and a patient services hub

> “Distribution and Patient Access Infrastructure. Subject to approval, we expect to utilize a distribution model that includes specialty pharmacy partners and centralized patient support services to facilitate access, benefits investigation, and reimbursement navigation, as needed. Our distribution strategy is intended to be developed in alignment with payer requirements, pharmacy network design, and anticipated utilization management approaches for OSA therapies. We also plan to establish a patient services hub to support prior authorization processes, affordability programs, and care coordination as needed, consistent with industry standards.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-2.1.2.11-4"></a>

### Planned field sales force and prescriber targets

> “Field Sales and Provider Engagement. We expect to deploy a targeted field sales organization of 125 to 150 representatives focused initially on covering 15,000 to 20,000 sleep specialists and high-volume primary care practices that manage patients with OSA. We also expect to deploy a small team targeting key OSA accounts and health systems.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

> “Planned Oxnimbi Promotional Launch Model”

Source: [Apnimed presentation (2026)](https://ir.apnimed.com/static-files/69419ee6-af17-4ba9-9b99-4fccd6e88177)

<a id="topic-2.1.2.11-5"></a>

### Planned launch sequence by patient segment

> “We intend to focus our initial launch phase of Oxnimbi, if approved, on the approximately 10.5 million people in the United States who are diagnosed with OSA but untreated, estimated based on the results of a survey conducted by the National Sleep Foundation in 2025”
> “Our long-term target market is patients seeking initial treatment, with Oxnimbi as a first-line solution, and analogs suggest that oral therapies are likely to evolve into first-line treatments over time.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-2.1.2.11-6"></a>

### Planned telehealth care pathways and durable medical equipment provider engagement

> “Subject to regulatory approval, we intend to partner with health systems, specialty telehealth providers, and virtual diagnostic platforms to support appropriate patient evaluation, diagnosis, and treatment initiation.”
> “If Oxnimbi is approved, we plan to engage where possible with DME organizations to help identify patients who are unable to initiate or sustain PAP therapy and who may require further clinical evaluation by their healthcare providers.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-2.1.2.11-7"></a>

### Manufacturing and commercial supply: contract manufacturers, no commercial supply agreements signed

> “We do not own or operate any manufacturing facilities.”
> “In the future, if Oxnimbi or any future product candidates are approved, we plan to enter into manufacturing and supply agreements with CMOs to support commercial scale production, but we do not have commercial supply agreements signed at this time.”
> “We have qualified primary and secondary suppliers for our API components of Oxnimbi, which have demonstrated adequate scale for our commercial supply needs and utilized these suppliers in our pre-commercial clinical studies supply program and registration stability batches.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-2.1.2.11-8"></a>

### Launch financing

> “$351.8 million in cash and cash equivalents as of September 30, 2026, expected to fund the potential U.S. launch of Oxnimbi and operations into the second quarter of 2028”

Source: [Apnimed third quarter results release (2026)](https://ir.apnimed.com/news-releases/news-release-details/apnimed-reports-third-quarter-2026-financial-results-and)

> “The capital is expected to support commercial readiness activities and the planned U.S. launch of Apnimed’s lead product candidate, AD109, if approved by the U.S. Food and Drug Administration (FDA).”

Source: [Apnimed debt financing release (2026)](https://ir.apnimed.com/news-releases/news-release-details/apnimed-secures-150-million-debt-financing-healthcare-royalty)

## Related pages
- [AD109 (aroxybutynin-atomoxetine): Obstructive sleep apnea](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Terms and abbreviations](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/terms-and-abbreviations.md)
- [AD109 (aroxybutynin-atomoxetine): Obstructive sleep apnea](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/executive-summary.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Product information and disease description](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Clinical evidence](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Economic information and modeling report](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/economics) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/economics.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: References](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/references) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/references.md)
